THE INDUSTRY’S LARGEST MARKETPLACE FOR PHARMACEUTICALS
steroidify.xyz has been in operation for almost 30 years, acquiring 50’s of thousands of satisfied customers.
steroidify.xyz works very hard to establish trust with our customer. Our high-quality products and professional staff is testament to the legitimacy of our business practice.
Each brand is hand-selected and goes through a very thorough review process.
Quality is held in a very high regard at steroidify.xyz. To further legitimize these products, we do have a comprehensive
Featured
Dbol 50
ACTIVE HALF-LIFE: 5-6 Hours CLASSIFICATION: Anabolic Steroid DOSAGE: Recommended range of 150-350mg per week AC..
Avana-100
ACTIVE HALF-LIFE 9-10 hours CLASSIFICATION PDE5 Inhibitor DOSAGE Men: 50-200 mg/day ACNE No WATER RETENTION ..
Lispro 10 mg
PRODUCT CATEGORY Angiotensin-Converting Enzyme (ACE) Inhibitors PRODUCER Johnlee Pharmaceuticals STORAGE LOCATION Int..
Stanozolex 25
ACTIVE HALF-LIFE 8 Hours CLASSIFICATION Anabolic Steroid DOSAGE 25-50 mg/day ACNE Yes WATER RETEN..
Testosterone Enanthate
ACTIVE HALF-LIFE 10 days CLASSIFICATION Anabolic Steroid DOSAGE Men 250-1000 mg/week ACNE Yes ..
Ultima-Caber
ACTIVE HALF-LIFE 63-68 hours CLASSIFICATION Prolactin Inhibitor ACNE Free from Acne Side Effects WATER RETENTIO..
Ultima-MTren
CARRIER OIL MCT Oil MANUFACTURER Ultima Pharmaceuticals - United States WAREHOUSE Located in USA Warehouse 5 ..
Hypho-Viagra
ACTIVE HALF-LIFE 5-12 hours CLASSIFICATION PDE5 Inhibitor DOSAGE Men 25-200 mg/day ACNE No WATER RETENTION ..
Fliban 100
ACNE No WATER RETENTION No HBR No HEPATOTOXICITY No AROMATIZATION No MANUFACTURER ..
Sustanon 250
ACTIVE HALF-LIFE 7-8 Days CLASSIFICATION Anabolic Steroid DOSAGE Men: 300-1500 mg/week ACNE Yes W..
Co-Diovan 160/12.5
MANUFACTURER Novartis - A Leader in Innovative Healthcare Solutions WAREHOUSE International Warehouse 2 - Your Reliable Source ..
Anastrozole
ACTIVE HALF-LIFE 2 days CLASSIFICATION Non-steroidal aromatase inhibitor DOSAGE 0.5-1 mg/day ACNE No WATER RETENTION No HBR No HEPATOTOXICITY No..












